Global, regional, and national quality of care index of cervical and ovarian cancer: a systematic analysis for the global burden of disease study 1990-2019.
Cervical cancer
Global burden of disease
Healthcare quality improvement
Ovarian cancer
Primary component analysis
Socio-demographic index
Journal
BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690
Informations de publication
Date de publication:
25 Jan 2024
25 Jan 2024
Historique:
received:
12
02
2023
accepted:
04
01
2024
medline:
26
1
2024
pubmed:
26
1
2024
entrez:
25
1
2024
Statut:
epublish
Résumé
Cervical cancer is the most preventable and ovarian cancer is the most lethal gynecological cancer. However, in the world, there are disparities in health care performances resulting in differences in the burden of these cancers. The objective of this study was to compare the health-system quality of care and inequities for these cancers using the Quality of Care Index (QCI). The 1990-2019 data of the Global Burden of Disease (GBD) was analyzed to extract rates of incidence, prevalence, mortality, Disability-Adjusted Life Years (DALYs), Years of Life Lost (YLL), and Years of healthy life lost due to disability (YLD) of cervical and ovarian cancer. Four indices were developed as a proxy for the quality of care using the above-mentioned rates. Thereafter, a Principal Components Analysis (PCA) was applied to construct the Quality of Care Index (QCI) as a summary measure of the developed indices. The incidence of cervical cancer decreased from 1990 to 2019, whereas the incidence of ovarian cancer increased between these years. However, the mortality rate of both cancers decreased in this interval. The global age-standardized QCI for cervical cancer and ovarian cancer were 43.1 and 48.5 in 1990 and increased to 58.5 and 58.4 in 2019, respectively. QCI for cervical cancer and ovarian cancer generally decreased with aging, and different age groups had inequitable QCIs. Higher-income countries generally had higher QCIs for both cancers, but exceptions were also observed. Uncovering disparities in cervical and ovarian cancer care across locations, Socio-Demographic Index levels, and age groups necessitate urgent improvements in healthcare systems for equitable care. These findings underscore the need for targeted interventions and prompt future research to explore root causes and effective strategies for narrowing these gaps.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Cervical cancer is the most preventable and ovarian cancer is the most lethal gynecological cancer. However, in the world, there are disparities in health care performances resulting in differences in the burden of these cancers. The objective of this study was to compare the health-system quality of care and inequities for these cancers using the Quality of Care Index (QCI).
MATERIAL AND METHODS
METHODS
The 1990-2019 data of the Global Burden of Disease (GBD) was analyzed to extract rates of incidence, prevalence, mortality, Disability-Adjusted Life Years (DALYs), Years of Life Lost (YLL), and Years of healthy life lost due to disability (YLD) of cervical and ovarian cancer. Four indices were developed as a proxy for the quality of care using the above-mentioned rates. Thereafter, a Principal Components Analysis (PCA) was applied to construct the Quality of Care Index (QCI) as a summary measure of the developed indices.
RESULTS
RESULTS
The incidence of cervical cancer decreased from 1990 to 2019, whereas the incidence of ovarian cancer increased between these years. However, the mortality rate of both cancers decreased in this interval. The global age-standardized QCI for cervical cancer and ovarian cancer were 43.1 and 48.5 in 1990 and increased to 58.5 and 58.4 in 2019, respectively. QCI for cervical cancer and ovarian cancer generally decreased with aging, and different age groups had inequitable QCIs. Higher-income countries generally had higher QCIs for both cancers, but exceptions were also observed.
CONCLUSIONS
CONCLUSIONS
Uncovering disparities in cervical and ovarian cancer care across locations, Socio-Demographic Index levels, and age groups necessitate urgent improvements in healthcare systems for equitable care. These findings underscore the need for targeted interventions and prompt future research to explore root causes and effective strategies for narrowing these gaps.
Identifiants
pubmed: 38273304
doi: 10.1186/s12905-024-02884-9
pii: 10.1186/s12905-024-02884-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
69Informations de copyright
© 2024. The Author(s).
Références
Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-Adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5(12):1749–68.
pubmed: 31560378
pmcid: 6777271
doi: 10.1001/jamaoncol.2019.2996
James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1789–858.
doi: 10.1016/S0140-6736(18)32279-7
Collins Y, Holcomb K, Chapman-Davis E, Khabele D, Farley JH. Gynecologic cancer disparities: A report from the Health Disparities Taskforce of the Society of Gynecologic Oncology. Gynecol Oncol. 2014;133:353–61 Academic Press Inc.
pubmed: 24406291
pmcid: 4079541
doi: 10.1016/j.ygyno.2013.12.039
Cibula D, Pötter R, Planchamp F, Avall-Lundqvist E, Fischerova D, HaieMeder C, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Radiother Oncol. 2018;127(3):404–16.
pubmed: 29728273
doi: 10.1016/j.radonc.2018.03.003
Aminorroaya A, Fattahi N, Azadnajafabad S, Mohammadi E, Jamshidi K, Rouhifard Khalilabad M, et al. Burden of non-communicable diseases in Iran: past, present, and future. J Diabetes Metab Disord. 2020;27:1–7.
WHO/Europe | European Observatory on Health Systems and Policies - Health system performance comparison. An agenda for policy, information and research . 2013. Available from: https://www.euro.who.int/en/about-us/partners/observatory/publications/studies/health-system-performance-comparison.-an-agenda-for-policy,-information-and-research-2013 . [Cited 2020 Nov 3].
Fullman N, Yearwood J, Abay SM, Abbafati C, Abd-Allah F, Abdela J, et al. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet. 2018;391(10136):2236–71.
doi: 10.1016/S0140-6736(18)30994-2
Khanali J, Malekpour MR, Azangou-Khyavy M, Saeedi Moghaddam S, Rezaei N, Kolahi AA, et al. Global, regional, and national quality of care of gallbladder and biliary tract cancer: a systematic analysis for the global burden of disease study 1990–2017. Int J Equity Health. 2021;20(1). Available from: https://pubmed.ncbi.nlm.nih.gov/34922531/ . [Cited 2023 Jan 31].
Azadnajafabad S, Saeedi Moghaddam S, Keykhaei M, Shobeiri P, Rezaei N, Ghasemi E, et al. Expansion of the quality of care index on breast cancer and its risk factors using the global burden of disease study 2019. Cancer Med. 2023;12(2). Available from: https://pubmed.ncbi.nlm.nih.gov/35770711/ . [Cited 2023 Jan 31].
Keykhaei M, Masinaei M, Mohammadi E, Azadnajafabad S, Rezaei N, Saeedi Moghaddam S, et al. A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017. Exp Hematol Oncol. 2021;10(1). Available from: https://pubmed.ncbi.nlm.nih.gov/33557940/ . [Cited 2023 Jan 31].
Abbasi-Kangevari M, Ahmadi N, Fattahi N, Rezaei N, Malekpour MR, Ghamari SH, et al. Quality of care of peptic ulcer disease worldwide: A systematic analysis for the global burden of disease study 1990–2019. PLoS One. 2022;17(8). Available from: https://pubmed.ncbi.nlm.nih.gov/35913985/ . [Cited 2023 Jan 31].
Ghamari SH, Yoosefi M, Abbasi-Kangevari M, Malekpour MR, Moghaddam SS, Shahin S, et al. Trends in Global, Regional, and National Burden and Quality of Care Index for Liver Cancer by Cause from Global Burden of Disease 1990–2019. Hepatol Commun. 2022;6(7):1764. Available from: https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep4.1910 . [Cited 2023 Jan 31].
pubmed: 35134275
pmcid: 9234674
doi: 10.1002/hep4.1910
Hanifiha M, Ghanbari A, Keykhaei M, Moghaddam SS, Rezaei N, Zanous MP, et al. Global, regional, and national burden and quality of care index in children and adolescents: A systematic analysis for the global burden of disease study 1990–2017. PLoS One. 2022;17(4). Available from: https://pubmed.ncbi.nlm.nih.gov/35472096/ . [Cited 2023 Jan 31].
Quality of Care Index (QCI). Available from: https://www.protocols.io/view/quality-of-care-index-qci-q26g78ym3lwz/v1 . [Cited 2023 Feb 11].
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet (London, England). 2020;396(10258):1204–22.
doi: 10.1016/S0140-6736(20)30925-9
GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1223–49.
doi: 10.1016/S0140-6736(20)30752-2
GBD Results Tool | GHDx. Available from: http://ghdx.healthdata.org/gbd-results-tool . [Cited 2021 Mar 3].
Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736–88.
doi: 10.1016/S0140-6736(18)32203-7
Mokdad AH, Mensah GA, Krish V, Glenn SD, Miller-Petrie MK, Lopez AD, et al. Global, regional, national, and subnational big data to inform health equity research: Persp ectives from the global burden of disease study 2017. Ethn Dis. 2019;29(Suppl 1):159–72.
pubmed: 30906165
pmcid: 6428171
doi: 10.18865/ed.29.S1.159
Methods of Multivariate Analysis - Alvin C. Rencher - Google Books. Available from: https://books.google.com/books?hl=en&lr=&id=SpvBd7IUCxkC&oi=fnd&pg=PR5&dq=methods+of+multivariate+analysis+1997+pdf&ots=IvSExAGbD2&sig=rh9zn5tqg6qZMsXYozfJy-c1K1U#v=onepage&q&f=false . [Cited 2020 Nov 3].
Moses MW, Pedroza P, Baral R, Bloom S, Brown J, Chapin A, et al. Funding and services needed to achieve universal health coverage: applications of global, regional, and national estimates of utilisation of outpatient visits and inpatient admissions from 1990 to 2016, and unit costs from 1995 to 2016. Lancet Public Health. 2019;4(1):e49-73.
pubmed: 30551974
doi: 10.1016/S2468-2667(18)30213-5
Mezei AK, Armstrong HL, Pedersen HN, Campos NG, Mitchell SM, Sekikubo M, et al. Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: a systematic review. Int J Cancer. 2017;141:437–46 Wiley-Liss Inc.
pubmed: 28297074
doi: 10.1002/ijc.30695
Ginsburg O, Bray F, Coleman MP, Vanderpuye V, Eniu A, Kotha SR, et al. The global burden of women’s cancers: a grand challenge in global health. Lancet. 2017;389:847–60 Lancet Publishing Group.
pubmed: 27814965
doi: 10.1016/S0140-6736(16)31392-7
Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393:169–82 Lancet Publishing Group.
pubmed: 30638582
doi: 10.1016/S0140-6736(18)32470-X
Kolawole Ogundari TA. Human capital contribution to economic growth in Sub-Saharan Africa: Does health status matter more than education? Econ Anal Policy. 2018;58:131–40.
doi: 10.1016/j.eap.2018.02.001
Matsuura Y, Yoshioka M, Nakata A, Haraga M, Hachisuga T, Mori K. Trends in uterine cervical cancer screening at physical health checkups for company employees in Japan. J UOEH. 2019;41(3):327–33.
pubmed: 31548487
doi: 10.7888/juoeh.41.327
Kaso M, Takahashi Y, Nakayama T. Factors related to cervical cancer screening among women of childrearing age: a cross-sectional study of a nationally representative sample in Japan. Int J Clin Oncol. 2019;24(3):313–22.
pubmed: 30276496
doi: 10.1007/s10147-018-1350-z
Berkhof J, Bogaards JA, Demirel E, Diaz M, Sharma M, Kim JJ. Cost-Effectiveness of Cervical Cancer Prevention in Central and Eastern Europe and Central Asia. Vaccine. 2013;31. Vaccine.
Sauvaget C, Nishino Y, Konno R, Tase T, Morimoto T, Hisamichi S. Challenges in breast and cervical cancer control in Japan. Lancet Oncol. 2016;17:e305-12 Lancet Publishing Group.
pubmed: 27396648
doi: 10.1016/S1470-2045(16)30121-8
Sano H, Goto R, Hamashima C. Does lack of resources impair access to breast and cervical cancer screening in Japan? PLoS One. 2017;12(7):e0180819.
pubmed: 28704430
pmcid: 5509210
doi: 10.1371/journal.pone.0180819
Sawaya GF, Huchko MJ. Cervical cancer screening. Med Clin North Am. 2017;101:743–53 W.B. Saunders.
pubmed: 28577624
pmcid: 6585416
doi: 10.1016/j.mcna.2017.03.006
Lew J Bin, Feletto E, Wade S, Caruana M, Kang YJ, Nickson C, et al. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates. Public Health Res Pract. 2019;29(2). Available from: https://pubmed.ncbi.nlm.nih.gov/31384886/ . [Cited 2023 Dec 20].
Pankakoski M, Sarkeala T, Anttila A, Heinävaara S. Effectiveness of Cervical Testing in and outside a Screening Program-A Case-Control Study. Cancers (Basel). 2022.;14(21). Available from: https://pubmed.ncbi.nlm.nih.gov/36358612/ [Cited 2023 Dec 20].
Hill EK. Updates in Cervical Cancer Treatment. Clin Obstet Gyneco. 2020;63(1):3–11. Available from: https://journals.lww.com/clinicalobgyn/fulltext/2020/03000/updates_in_cervical_cancer_treatment.3.aspx . [Cited 2023 Dec 21].
doi: 10.1097/GRF.0000000000000507
Aimagambetova G, Azizan A. Epidemiology of HPV infection and HPV-related cancers in Kazakhstan: a review. Asian Pac J Cancer Prev. 2018;19:1175–80 Asian Pacific Organization for Cancer Prevention.
pubmed: 29801397
pmcid: 6031825
Dhamija S, Sehgal A, Luthra UK, Sehgal K. Factors associated with awareness and knowledge of cervical cancer in a community: implication for health education programmes in developing countries. J R Soc Promot Health. 1993;113(4):184–6.
Siziya PhDS, Kabalika MBChBC, Mulenga MPHD, Mazaba, MSc ML. Acceptance of Cervical Cancer Screening and its Correlates Among Women of a Peri-Urban High-Density Residential Area in Ndola, Zambia. International Journal of MCH and AIDS (IJMA). 2018;7(1):17–27.
pubmed: 30305986
doi: 10.21106/ijma.223
Ouasmani F, Hanchi Z, HaddouRahou B, Bekkali R, Ahid S, Mesfioui A. Determinants of patient delay in seeking diagnosis and treatment among moroccan women with cervical cancer. Obstet Gynecol Int. 2016;2016:4840762.
pubmed: 27882055
pmcid: 5110862
doi: 10.1155/2016/4840762
Wegwarth O, Widschwendter M, Cibula D, Sundström K, Portuesi R, Lein I, et al. What do European women know about their female cancer risks and cancer screening? A cross-sectional online intervention survey in five European countries. BMJ Open. 2018;8(12):e023789.
pubmed: 30593552
pmcid: 6318519
doi: 10.1136/bmjopen-2018-023789
Ruggles BM, Xiong A, Kyle B. Healthcare coverage in the US and Japan: A comparison. Nursing (Brux). 2019;49(4):56–60. Available from: https://pubmed.ncbi.nlm.nih.gov/30893207/ . [Cited 2023 Dec 20].
doi: 10.1097/01.NURSE.0000553277.03472.d8
Kokawa K, Takekida S, Kamiura S, Kita M, Enomoto T, Kawaguchi R, et al. The incidence, treatment and prognosis of cervical carcinoma in young women: A retrospective analysis of 4,975 cases in Japan. Eur J Gynaecol Oncol. 2010;31:37–43. Available from: https://pubmed.ncbi.nlm.nih.gov/20349779/ . [Cited 2020 Nov 4].
pubmed: 20349779
Quinn BA, Deng X, Colton A, Bandyopadhyay D, Carter JS, Fields EC. Increasing age predicts poor cervical cancer prognosis with subsequent effect on treatment and overall survival. Brachytherapy. 2019;18(1):29–37.
pubmed: 30361045
doi: 10.1016/j.brachy.2018.08.016
Mohammadi E, Aminorroaya A, Fattahi N, Azadnajafabad S, Rezaei N, Farzi Y, Naderimagham S, Rezaei N, Larijani B, Farzadfar F. Epidemiologic pattern of cancers in Iran; current knowledge and future perspective. J Diabetes Metab Disord. 2020;20(1):825–29. https://doi.org/10.1007/s40200-020-00654-6 .
Campos NG, Maza M, Alfaro K, Gage JC, Castle PE, Felix JC, et al. The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador. Int J Cancer. 2015;137(4):893–902.
pubmed: 25639903
doi: 10.1002/ijc.29438
Arbyn M, Xu L. Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials. Expert Rev Vaccines. 2018;17:1085–91 Taylor and Francis Ltd.
pubmed: 30495978
doi: 10.1080/14760584.2018.1548282
Campos NG, Castle PE, Wright TC, Kim JJ. Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage. Int J Cancer. 2015;137(9):2208–19.
pubmed: 25943074
pmcid: 4910518
doi: 10.1002/ijc.29594
Diaz M, Kim JJ, Albero G, De Sanjosé S, Clifford G, Bosch FX, et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer. 2008;99(2):230–8.
pubmed: 18612311
pmcid: 2480962
doi: 10.1038/sj.bjc.6604462
Ginsberg GM, Edejer TTT, Lauer JA, Sepulveda C. Screening, prevention and treatment of cervical cancer-A global and regional generalized cost-effectiveness analysis. Vaccine. 2009;27(43):6060–79.
pubmed: 19647813
doi: 10.1016/j.vaccine.2009.07.026
Cress RD, Chen YS, Morris CR, Petersen M, Leiserowitz GS. Characteristics of long-term survivors of epithelial ovarian cancer. Obstet Gynecol. 2015;126(3):491–7.
pubmed: 26244529
pmcid: 4545401
doi: 10.1097/AOG.0000000000000981
Greggi S, Parazzini F, Paratore MP, Chatenoud L, Legge F, Mancuso S, et al. Risk factors for ovarian cancer in central Italy. Gynecol Oncol. 2000;79(1):50–4.
pubmed: 11006030
doi: 10.1006/gyno.2000.5909
Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: Systematic review and meta-analysis. J Nat Cancer Inst. 2014;106. Oxford University Press.
Park B, Park S, Shin HR, Shin A, Yeo Y, Choi JY, et al. Population attributable risks of modifiable reproductive factors for breast and ovarian cancers in Korea. BMC Cancer. 2016;16(1):5.
pubmed: 26732868
pmcid: 4702325
doi: 10.1186/s12885-015-2040-0
Trabert B, Ness RB, Lo-Ciganic WH, Murphy MA, Goode EL, Poole EM, et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: A pooled analysis in the ovarian cancer association consortium. J Natl Cancer Inst. 2014;106(2):djt431.
pubmed: 24503200
pmcid: 3924755
doi: 10.1093/jnci/djt431
Zhang M, Yang ZY, Binns CW, Lee AH. Diet and ovarian cancer risk: a case-control study in China. Br J Cancer. 2002;86(5):712–7.
pubmed: 11875731
pmcid: 2375319
doi: 10.1038/sj.bjc.6600085
Pan SY, Ugnat AM, Mao Y, Paulse B, Dewar R, Dryer D, et al. Physical activity and the risk of ovarian cancer: a case-control study in Canada. Int J Cancer. 2005;117(2):300–7.
pubmed: 15898119
doi: 10.1002/ijc.21157
Yoon SH, Kim SN, Shim SH, Kang SB, Lee SJ. Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: a meta-analysis. Eur J Cancer. 2016;1(55):38–46.
doi: 10.1016/j.ejca.2015.12.003
Rice MS, Hankinson SE, Tworoger SS. Tubal ligation, hysterectomy, unilateral oophorectomy, and risk of ovarian cancer in the Nurses’ Health Studies. Fertil Steril. 2014;102(1):192-198.e3.
pubmed: 24825424
pmcid: 4074555
doi: 10.1016/j.fertnstert.2014.03.041
Rice MS, Murphy MA, Tworoger SS. Tubal ligation, hysterectomy and ovarian cancer: A meta-analysis. J Ovarian Res. 2012;5(1):13.
pubmed: 22587442
pmcid: 3386864
doi: 10.1186/1757-2215-5-13
Cabanes A, Vidal E, Pérez-Gómez B, Aragonés N, López-Abente G, Pollán M. Age-specific breast, uterine and ovarian cancer mortality trends in Spain: Changes from 1980 to 2006. Cancer Epidemiol. 2009;33(3–4):169–75.
pubmed: 19766076
doi: 10.1016/j.canep.2009.08.010
Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol. 2006;108(3):521–8.
pubmed: 16946210
doi: 10.1097/01.AOG.0000231680.58221.a7
Chiang YC, Chen CA, Chiang CJ, Hsu TH, Lin MC, You SL, et al. Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan. J Gynecol Oncol. 2013;24(4):342–51.
pubmed: 24167670
pmcid: 3805915
doi: 10.3802/jgo.2013.24.4.342